■促性腺激素释放激素(GnRH)类似物用于防止体外受精期间黄体生成素(LH)过早激增。然而,胎盘生长因子(FFPlGF)的卵泡液水平,新的血管生成因子,GnRH激动剂和GnRH拮抗剂方案之间存在显着差异。因此,我们比较了多囊卵巢综合征(PCOS)和正常排卵女性在不同过度刺激方案下的IVF/ICSI结局及其与FFPlGF水平的相关性.
这项病例对照研究是对两项在东方医院转诊的女性进行的前瞻性试验的再分析。大马士革,叙利亚,从2019年12月到2021年8月。共有75名PCOS女性(PCOS激动剂,n=53;PCOS拮抗剂,n=22)和83名正常排卵妇女(控制激动剂,n=50;对照拮抗剂,包括n=33)。在取回日收集卵泡液样品。
■尽管PCOS女性使用较低剂量的促性腺激素刺激,PCOS组的卵巢敏感性指数较高(PCOS激动剂vs对照激动剂;P值<0.001),(PCOS-拮抗剂与对照-拮抗剂;P值=0.042)。然而,FFPlGF等级,成熟率,受精率,和卵母细胞形态在PCOS和对照组之间具有可比性,而与所使用的方案无关。有趣的是,在PCOS拮抗剂中,FFPlGF水平与卵巢敏感性指数呈正相关,控制激动剂,和控制安踏集团,但在PCOS激动剂组中没有。然而,在所有研究组中,孕妇和非孕妇之间的FFPlGF水平相当。
■尽管无论使用何种方案,PCOS都会夸大卵巢对刺激的反应,它对卵母细胞形态或能力没有不利影响。此外,FFPlGF水平可能是卵巢反应的标志物,而不是妊娠成就的预测指标。
UNASSIGNED: Gonadotropin-releasing hormone (GnRH) analogues are used to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization. However, the follicular fluid levels of the Placental growth factor (FF PlGF), the novel angiogenic factor, differ significantly between GnRH-agonist and GnRH-antagonist protocols. Thus, we compared the IVF/ICSI outcomes and their correlations with FF PlGF levels in polycystic ovary syndrome (PCOS) and normo-ovulatory women during different hyperstimulation protocols.
UNASSIGNED: This
case-control study is a re-analysis of two prospective trials that were conducted on women who were referred to Orient Hospital, Damascus, Syria, from December 2019 to August 2021. A total of 75 PCOS-women (PCOS-Agonist, n = 53; PCOS-Antagonist, n = 22) and 83 normo-ovulatory women (Control-Agonist, n = 50; Control-Antagonist, n = 33) were included. Follicular fluid samples were collected on retrieval day.
UNASSIGNED: Although PCOS-women were stimulated using lower gonadotropin doses, the Ovarian-sensitivity-indexes were higher in PCOS-groups (PCOS-Agonist vs Control-Agonist; P-value <0.001), (PCOS-Antagonist vs Control-Antagonist; P-value = 0.042). However, FF PlGF levels, maturation rate, fertilization rate, and oocytes morphology were comparable between PCOS and controls independently of the protocol used. Interestingly, FF PlGF levels were positively correlated with Ovarian-sensitivity-indexes in the PCOS-Antagonist, Control-Agonist, and Control-Anta groups, but not in the PCOS-Agonist group. Nevertheless, FF PlGF levels were comparable between pregnant and non-pregnant women in all studied groups.
UNASSIGNED: Although PCOS exaggerates ovarian response to stimulation irrespective of the protocol used, it does not have a detrimental impact on oocytes morphology or competence. Moreover, FF PlGF levels could be a marker of the ovarian response other than a predictor of pregnancy achievement.